 |
2 Diseases |  |
40 Trials |
|
40 Trials |  |
1659 News |  |
| «12...6789101112131415161718» |
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] To investigate the response to luspatercept as a function of the ß-globin genotype in adult patients with ß-thalassemia in the BELIEVE study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1577;
P3
Clinically meaningful reductions in TB were observed across genotypes, although response rates were lower in pts with the most severe disease (β0/β0).
- Jakafi oral (ruxolitinib) / Novartis, Incyte, Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] New approaches to the therapy of beta thalassemia (Osaka) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1418;
Ineffective erythropoiesis caused by TGF-b superfamily ligands via activin receptors and SMAD4-signaling is targeted through the activin receptor ligand trap luspatercept...In animal models, the JAK-Inhibitor ruxolitinib reduced early erythroid precursor proliferation and increased their differentiation...The major future challenge will be not only to find the right single option for an individual patient but also to develop strategies for combining different approaches with the aim of maximum efficacy in parallel to maximum safety. Finally, careful adherence to an optimally designed standard-of-care treatment using transfusion and chelation will be prerequisite to enable patients to benefit from those innovative approaches in the future.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Reduction of transfusion dependency of red cell concentrates in the phase III MEDALIST study on luspatercept in low-risk MDS patients (LR-MDS) with ring sideroblasts (RS) (Montreal) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1399;
P3
Finally, careful adherence to an optimally designed standard-of-care treatment using transfusion and chelation will be prerequisite to enable patients to benefit from those innovative approaches in the future. Luspatercept demonstrated clinical efficacy and was associated with significant reductions in RBC transfusions (≥50%) and serum ferritin.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] To investigate the response to luspatercept as a function of the ß-globin genotype in adult patients with ß-thalassemia in the BELIEVE study (Samarkand) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1139;
P3
Luspatercept demonstrated clinical efficacy and was associated with significant reductions in RBC transfusions (≥50%) and serum ferritin. Clinically meaningful reductions in TB were observed across genotypes, although response rates were lower in pts with the most severe disease (β0/β0).
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Determination of the dose-dependent response rate to luspatercept in patients with low-risk MDS (LR-MDS) with ring sideroblasts (RS) in the phase III MEDALIST study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_984;
P3
The majority of pts with baseline TB ≤6 RBC units/8 wks who achieved RBC-TI ≥8 wks within the first 48 wks achieved their first response at 1.0 mg/kg. The dose range of 1.0-1.75 mg/kg was well tolerated.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Reduction of transfusion dependency of red cell concentrates in the phase III MEDALIST study on luspatercept in low-risk MDS patients (LR-MDS) with ring sideroblasts (RS) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_980;
P3
The dose range of 1.0-1.75 mg/kg was well tolerated. Luspatercept demonstrated clinical efficacy and was associated with significant reductions in RBC transfusions (≥50%) and serum ferritin.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Long-term effectiveness and therapy-associated adverse events in the phase 3 BELIEVE study on luspatercept in the treatment of patients with ß-thalassemia (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_927;
P3
Luspatercept demonstrated clinical efficacy and was associated with significant reductions in RBC transfusions (≥50%) and serum ferritin. Luspatercept was associated with prolonged periods of clinically meaningful TB reductions, including in crossover pts.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] To investigate the response to luspatercept as a function of the ß-globin genotype in adult patients with ß-thalassemia in the BELIEVE study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_926;
P3
Luspatercept was associated with prolonged periods of clinically meaningful TB reductions, including in crossover pts. Clinically meaningful reductions in TB were observed across genotypes, although response rates were lower in pts with the most severe disease (β0/β0).
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Determination of the dose-dependent response rate to luspatercept in patients with low-risk MDS (LR-MDS) with ring sideroblasts (RS) in the phase III MEDALIST study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_144;
P3
The majority of pts with baseline TB ≤6 RBC units/8 wks who achieved RBC-TI ≥8 wks within the first 48 wks achieved their first response at 1.0 mg/kg. The dose range of 1.0-1.75 mg/kg was well tolerated.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Reduction of transfusion dependency of red cell concentrates in the phase III MEDALIST study on luspatercept in low-risk MDS patients (LR-MDS) with ring sideroblasts (RS) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_140;
P3
The dose range of 1.0-1.75 mg/kg was well tolerated. Luspatercept demonstrated clinical efficacy and was associated with significant reductions in RBC transfusions (≥50%) and serum ferritin.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Long-term effectiveness and therapy-associated adverse events in the phase 3 BELIEVE study on luspatercept in the treatment of patients with ß-thalassemia (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_87;
P3
Luspatercept demonstrated clinical efficacy and was associated with significant reductions in RBC transfusions (≥50%) and serum ferritin. Luspatercept was associated with prolonged periods of clinically meaningful TB reductions, including in crossover pts.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] To investigate the response to luspatercept as a function of the ß-globin genotype in adult patients with ß-thalassemia in the BELIEVE study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_86;
P3
Luspatercept was associated with prolonged periods of clinically meaningful TB reductions, including in crossover pts. Clinically meaningful reductions in TB were observed across genotypes, although response rates were lower in pts with the most severe disease (β0/β0).
- || Reblozyl (luspatercept-aamt) / Acceleron, BMS
Apparently Reblozyl sounds like Red Blood cell (if you are missing all of your teeth :) (Twitter) - Sep 1, 2020
- |||| azacitidine oral (CC-486) / BMS, Reblozyl (luspatercept-aamt) / Acceleron, BMS
Clinical, FDA event: CC-486 / oral azacitidine #FDA approved for #AML maintenance therapy - good to have. I wish Celgene would consult me about trade names before marketing, though - “Onureg” sounds too much like “Anuric” 😜 not to mention this year’s earlier approval of “Reblozyl” (Twitter) - Sep 1, 2020
- |||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date, Trial primary completion date: LTFU: A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (clinicaltrials.gov) - Aug 7, 2020
P3b, N=665, Recruiting, Sponsor: Celgene
Clinically meaningful reductions in TB were observed across genotypes, although response rates were lower in pts with the most severe disease (β0/β0). Trial completion date: Jan 2028 --> Mar 2030 | Trial primary completion date: Jan 2028 --> Mar 2030
- | Journal: Lowering the boom on lower-risk myelodysplastic syndromes. (Pubmed Central) - Aug 6, 2020
Newer agents on the horizon are abrogating the downstream sequelae of specific molecular mutations. One challenge for the future is in further modifying response criteria to align with improvements that are clinically meaningful to patients.
- || azacitidine / Generic mfg.
Review, Journal: Targeting the Microenvironment in MDS: The Final Frontier. (Pubmed Central) - Aug 4, 2020
Therefore, successful therapies in MDS should not only target the malignant cells but also reprogram their bone marrow microenvironment. Here, we will provide a synopsis of how drugs currently used or on the verge of being approved for the treatment of MDS may achieve this goal.
- | sotatercept (ACE-011) / Acceleron, BMS, Reblozyl (luspatercept-aamt) / Acceleron, BMS
Review, Journal: Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS. (Pubmed Central) - Jul 29, 2020
A phase III randomized clinical trial with luspatercept was recently conducted. Activin receptor II ligand traps may represent a new paradigm for anemia treatment in MDS.
- || Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New P2 trial: A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions (clinicaltrials.gov) - Jul 20, 2020
P2, N=30, Not yet recruiting, Sponsor: Celgene
- ||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date: COMMANDS: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na (clinicaltrials.gov) - Jul 16, 2020
P3, N=350, Recruiting, Sponsor: Celgene
Activin receptor II ligand traps may represent a new paradigm for anemia treatment in MDS. Trial completion date: Dec 2026 --> Sep 2023
- [VIRTUAL] New Approaches for Anemia in MDS () - Jul 14, 2020 - Abstract #SOHO2020SOHO_105;
P2/3, P3
However, a phase 3 placebo-controlled study including only intermediate-1 risk MDS patients with RBC-TD and thrombocytopenia (NCT01566695) has recently been prematurely terminated, mainly because of toxicity.20 Beyond the described substances, other areas of translational research involve targeting the inflammasome by anti-inflammatory drugs in order to improve anemia. All these efforts will hopefully pave the way for new treatment options in the setting of anemic lower-risk MDS patients and improve outcomes in the near future.
- ||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With ?-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) (clinicaltrials.gov) - Jul 14, 2020
P2, N=51, Completed, Sponsor: Acceleron Pharma, Inc.
All these efforts will hopefully pave the way for new treatment options in the setting of anemic lower-risk MDS patients and improve outcomes in the near future. Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> Jun 2020 | Trial primary completion date: Feb 2020 --> Jun 2020
- ||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) (clinicaltrials.gov) - Jul 14, 2020
P2, N=75, Completed, Sponsor: Acceleron Pharma, Inc.
Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> Jun 2020 | Trial primary completion date: Feb 2020 --> Jun 2020 Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> May 2020 | Trial primary completion date: Apr 2022 --> May 2020
- | Reblozyl (luspatercept-aamt) / Acceleron, BMS
@NICEComms get on with this and approve. #luspatercept (Twitter) - Jun 30, 2020
- |||| Reblozyl (luspatercept-aamt) / Acceleron, BMS
Clinical: I've got a question @VPrasadMDMPH @AlisonPalumbo and others.. luspatercept was studied in hypomethylator naive patients. Undoubtedly going to extrapolate and use for this population. Stop the hypomethylating agent? Use in combo seems to muddy the waters. (Twitter) - Jun 25, 2020
- || Reblozyl (luspatercept-aamt) / Acceleron, BMS
Review, Journal: Luspatercept: First Approval. (Pubmed Central) - Jun 25, 2020
Based primarily on the results of the phase III BELIEVE trial, subcutaneous luspatercept was recently approved in the USA for the treatment of anaemia associated with beta-thalassaemia. This article summarizes the milestones in the development of luspatercept leading to this first approval.
- |||| Reblozyl (luspatercept-aamt) / Acceleron, BMS
Outstanding talk by @DavidSteensma at @EHA_Hematology #EHA25Virtual #EHA25 #eha I agree with new definition and feel comfortable to use ESA (potentially luspatercept ?) in setting of no other cause for anemia-Thoughts? @MikkaelSekeres @Ramikomrokji @MrinalPatnaik @garciamanero (Twitter) - Jun 22, 2020
- | Journal: Novel therapies in low- and high-risk myelodysplastic syndrome. (Pubmed Central) - Jun 15, 2020
Combinations of hypomethylating agents (HMA) with other compounds, and inhibitors of bcl2, such as venetoclax are being developed for higher-risk patients. Finally, hypomethylating agents in combination with donor lymphocytes may lead to long-term remission following molecular or hematological relapse after allogeneic SCT.
- | Venclexta (venetoclax) / Roche, AbbVie, Revlimid (lenalidomide) / BMS, Reblozyl (luspatercept-aamt) / Acceleron, BMS
Journal: Management of myelodysplastic syndromes in 2019: An update (Pubmed Central) - May 17, 2020
New molecules are being studied with some interesting results (luspatercept, venetoclax). This article aims to provide an update on the knowledge that an internist should know for the practical management of myelodysplastic syndromes in 2019.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] ASSESSMENT OF LONGER-TERM EFFICACY AND SAFETY IN THE PHASE 3 BELIEVE TRIAL OF LUSPATERCEPT TO TREAT ANEMIA IN PATIENTS (PTS) WITH Β-THALASSEMIA () - May 16, 2020 - Abstract #EHA2020EHA_1916;
P3
Conclusion Luspatercept treatment was associated with prolonged periods of clinically meaningful reductions in transfusion burden, including in pts who crossed over from the PBO arm. The safety profile of crossover pts did not substantially change for the most frequent TEAEs.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] LONGER-TERM RED BLOOD CELL (RBC) TRANSFUSION REDUCTION IN THE PHASE 3 MEDALIST STUDY OF LUSPATERCEPT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) WITH RING SIDEROBLASTS (RS) () - May 16, 2020 - Abstract #EHA2020EHA_1430;
P3
In Weeks 1–24, 38/127 (29.9%) vs 5/65 (7.7%) patients (P=0.0005) achieved major hematologic improvement–erythroid (HI-E) response per International Working Group 2018 criteria in the luspatercept vs placebo arms, respectively. Conclusion Luspatercept demonstrated clinically meaningful responses in patients with LR-MDS with RS and was associated with statistically significant reductions in RBC transfusions (≥50%; P<0.0001) and serum ferritin (P=0.0024 in Weeks 9–24; P=0.0294 in Weeks 33–48).
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] ASSESSMENT OF DOSE-DEPENDENT RESPONSE TO LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) WITH RING SIDEROBLASTS IN THE PHASE 3 MEDALIST TRIAL () - May 16, 2020 - Abstract #EHA2020EHA_1429;
P3
An additional 11% of pts in this group (and ~17% of responders overall) achieved their first response only with higher doses (1.33 and 1.75 mg/kg) and dose escalations contributed to maintenance of response or achievement of multiple response episodes. The dose range of 1.0–1.75 mg/kg was well tolerated, without dose-dependent increases in TEAEs.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] EFFECTS OF LUSPATERCEPT ON SERUM FERRITIN IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITH RING SIDEROBLASTS (RS) IN THE PHASE 3 MEDALIST TRIAL () - May 16, 2020 - Abstract #EHA2020EHA_1424;
P3
This suggests that the effect of luspatercept on serum ferritin may be due not only to transfusion reduction, but also potentially to a more direct effect of the drug on ineffective erythropoiesis and/or iron metabolism. Overall, ICT use was reduced with luspatercept.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] CLINICAL BENEFIT OF LUSPATERCEPT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) AND HIGH TRANSFUSION BURDEN (HTB) IN THE PHASE 3 MEDALIST STUDY () - May 16, 2020 - Abstract #EHA2020EHA_1415;
P3
Conclusion Luspatercept treatment resulted in clinically significant reductions in transfusion burden and reduced number of transfusion events in HTB patients with LR-MDS with RS. Luspatercept was well tolerated in HTB patients, consistent with the overall study population.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] EFFECT OF LUSPATERCEPT (RAP-536) ON MDS PDX-MURINE MODELS WITH OR WITHOUT SF3B1 MUTATION () - May 16, 2020 - Abstract #EHA2020EHA_1395;
Moreover, we did not observe any modification concerning the variance in allele frequencies in mice treated or not with RAP-536. Conclusion RAP-536 seems to enhance the engraftment of human CD45+/CD33+in this PDX murine models without any impact on clonal architecture
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] ASSESSMENT OF RESPONSE TO LUSPATERCEPT BY Β-GLOBIN GENOTYPE IN ADULT PATIENTS WITH Β-THALASSEMIA IN THE BELIEVE TRIAL () - May 16, 2020 - Abstract #EHA2020EHA_579;
P3
The incidence of specific adverse events was consistent with the overall population. Conclusion Although response rates were lower in pts with the most severe disease (β0/β0), clinically meaningful reductions in transfusion burden were observed across genotypes.
- | Reblozyl (luspatercept-aamt) / Acceleron, BMS
#EHA2020 Luspatercept Abstracts $XLRN $BMY https://t.co/EnO7BFcH5o (Twitter) - May 14, 2020
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
Evaluating luspatercept responders in the phase 3, randomised, double‐blind, placebo‐controlled BELIEVE trial of luspatercept in adult beta‐thalassaemia patients who require regular red blood cell transfusions () - May 14, 2020 - Abstract #BSH2020BSH_418;
P3
Most luspatercept responders experienced multiple episodes of meaningful transfusion reduction and had durable clinical benefit over time. Luspatercept treatment in adult patients with beta‐thalassaemia who require regular RBC transfusions resulted in a significant reduction in RBC transfusion burden, with an acceptable safety profile.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
Effects of luspatercept on iron overload and impact on responders to luspatercept: results from the BELIEVE Trial () - May 14, 2020 - Abstract #BSH2020BSH_354;
P3
Luspatercept treatment resulted in statistically significant reductions in serum ferritin, and there was a trend for decrease in liver iron concentration. These data suggest that luspatercept may contribute to improved control of body iron in patients with beta‐thalassaemia who require regular RBC transfusions, particularly in those achieving at least a 33% reduction in RBC transfusion burden.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
Assessment of longer‐term efficacy, safety, and haematological improvement in the phase 3, randomised, double‐blind, placebo‐controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower‐risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions () - May 14, 2020 - Abstract #BSH2020BSH_340;
P3
In the few patients with baseline neutropenia or thrombocytopenia receiving luspatercept, cytopenias did not worsen following treatment. Luspatercept is a potential new therapy for the treatment of anaemia in patients with LR‐MDS with RS.
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower‐risk myelodysplastic syndromes enrolled in the MEDALIST trial () - May 14, 2020 - Abstract #BSH2020BSH_98;
P3
Luspatercept is a potential new therapy for the treatment of anaemia in patients with LR‐MDS with RS, regardless of the number of associated mutations. Further study of the predictors of response is warranted.
- ||||| Reblozyl (luspatercept-aamt) / Acceleron, BMS
WATCH: @Ramikomrokji @MoffittNews @DrEllenRitchie @WeillCornell @MikkaelSekeres @ClevelandClinic and Dr. Jamile Shammo @RushMedical discuss the phase 3 MEDALIST trial of luspatercept for MDS. Learn more: https://t.co/ywC987aLMG (Twitter) - May 8, 2020
- ||| Venclexta (venetoclax) / Roche, AbbVie, Reblozyl (luspatercept-aamt) / Acceleron, BMS
Thanks again @Mohty_EBMT @doctorpemm for a very clear and helpful @TheIACH webinar on #aml #all #mds. And for adressing our question re compassionate and/or off label use of #venetoclax and #luspatercept. Obvious it would help a lot during #COVID19 Thks for all you do #staysafe (Twitter) - May 5, 2020
- || Reblozyl (luspatercept-aamt) / Acceleron, BMS, Daurismo (glasdegib) / Pfizer
AML drug glasdegib and MDS drug luspatercept approved in Europe. https://t.co/NttH7THg6v (Twitter) - May 2, 2020
- || Reblozyl (luspatercept-aamt) / Acceleron, BMS
EU Panel Backs Luspatercept for Anemia in MDS and Beta Thalassemia https://t.co/AoFy07D7eT (Twitter) - Apr 30, 2020
- | Reblozyl (luspatercept-aamt) / Acceleron, BMS, Daurismo (glasdegib) / Pfizer
Crunch Time At EMA For Luspatercept And Glasdegib https://t.co/ZlQeOA4n8w #PinkSheet (Twitter) - Apr 30, 2020
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study. (Poster Board 327) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2095;
P3
Luspatercept treatment resulted in clinically significant reductions in transfusion burden and reduced number of transfusion events in HTB pts with LR-MDS with RS, with an acceptable safety profile consistent with the overall population. Research Funding: Bristol-Myers Squibb in collaboration with Acceleron Pharma
- Reblozyl (luspatercept-aamt) / Acceleron, BMS
[VIRTUAL] Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS). (Poster Board 291) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2058;
P3
Luspatercept demonstrated clinical efficacy in pts with LR-MDS with RS and was associated with significant reductions in RBC transfusions (≥ 50%) and serum ferritin. Research Funding: Bristol-Myers Squibb in collaboration with Acceleron Pharma
- || Tukysa (tucatinib) / Seattle Genetics, Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Reblozyl (luspatercept-aamt) / Acceleron, BMS
OMG Julia and @christeeny513 ...to think we were laughing about Tukysa and Trodelvy! Seriously, can someone please admit there is a secret contest for most ridiculous drug name?!? KOSELUGO? JELMYTO? REBLOZYL? 🤣🤣🤣 (Twitter) - Apr 26, 2020
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date: BEYOND: A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (?)-Thalassemia (clinicaltrials.gov) - Apr 19, 2020
P2, N=145, Active, not recruiting, Sponsor: Celgene
Research Funding: Bristol-Myers Squibb in collaboration with Acceleron Pharma Trial completion date: Jan 2021 --> Mar 2022